148 related articles for article (PubMed ID: 10563513)
1. Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.
Wang JS; Wen X; Backman JT; Taavitsainen P; Neuvonen PJ; Kivistö KT
Pharmacol Toxicol; 1999 Oct; 85(4):157-61. PubMed ID: 10563513
[TBL] [Abstract][Full Text] [Related]
2. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.
von Moltke LL; Greenblatt DJ; Schmider J; Duan SX; Wright CE; Harmatz JS; Shader RI
J Clin Pharmacol; 1996 Sep; 36(9):783-91. PubMed ID: 8889898
[TBL] [Abstract][Full Text] [Related]
3. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
Ma B; Prueksaritanont T; Lin JH
Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
[TBL] [Abstract][Full Text] [Related]
4. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
[TBL] [Abstract][Full Text] [Related]
5. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
[TBL] [Abstract][Full Text] [Related]
6. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.
Yamano K; Yamamoto K; Kotaki H; Sawada Y; Iga T
Drug Metab Dispos; 1999 Mar; 27(3):395-402. PubMed ID: 10064572
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes.
Back DJ; Tjia JF
Br J Clin Pharmacol; 1991 Nov; 32(5):624-6. PubMed ID: 1659439
[TBL] [Abstract][Full Text] [Related]
8. In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes.
Kuroha M; Kuze Y; Shimoda M; Kokue E
Am J Vet Res; 2002 Jun; 63(6):900-5. PubMed ID: 12061540
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes.
Yeo KR; Yeo WW
Br J Clin Pharmacol; 2001 May; 51(5):461-70. PubMed ID: 11422004
[TBL] [Abstract][Full Text] [Related]
10. The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes.
Luo X; Li T; Yu Z; Xue X; Zhao H; Li N; Ma L; Yang C; Huang L; Feng W
Xenobiotica; 2019 Jul; 49(7):753-761. PubMed ID: 29770723
[TBL] [Abstract][Full Text] [Related]
11. Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.
Zhao XJ; Ishizaki T
Br J Clin Pharmacol; 1997 Nov; 44(5):505-11. PubMed ID: 9384469
[TBL] [Abstract][Full Text] [Related]
12. Azoles, allylamines and drug metabolism.
Back DJ; Tjia JF; Abel SM
Br J Dermatol; 1992 Feb; 126 Suppl 39():14-8. PubMed ID: 1311943
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies.
Hamaoka N; Oda Y; Hase I; Asada A
Br J Anaesth; 2001 Apr; 86(4):540-4. PubMed ID: 11573629
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
Gibbs MA; Thummel KE; Shen DD; Kunze KL
Drug Metab Dispos; 1999 Feb; 27(2):180-7. PubMed ID: 9929500
[TBL] [Abstract][Full Text] [Related]
15. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
Wang YH; Jones DR; Hall SD
Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501
[TBL] [Abstract][Full Text] [Related]
16. Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole.
Zhuang X; Zhang T; Yue S; Wang J; Luo H; Zhang Y; Li Z; Che J; Yang H; Li H; Zhu M; Lu C
Biochem Pharmacol; 2016 Dec; 121():67-77. PubMed ID: 27666601
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.
Shirasaka Y; Chang SY; Grubb MF; Peng CC; Thummel KE; Isoherranen N; Rodrigues AD
Drug Metab Dispos; 2013 Aug; 41(8):1566-74. PubMed ID: 23723360
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes.
Lukkari E; Taavitsainen P; Juhakoski A; Pelkonen O
Pharmacol Toxicol; 1998 Apr; 82(4):161-6. PubMed ID: 9584328
[TBL] [Abstract][Full Text] [Related]
19. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
20. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.
Wang JS; Backman JT; Wen X; Taavitsainen P; Neuvonen PJ; Kivistö KT
Pharmacol Toxicol; 1999 Nov; 85(5):201-5. PubMed ID: 10608481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
